Xeris Pharmaceuticals (XERS) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

XERS Xeris Pharmaceuticals

Watchlist

3.490
+0.080+2.35%

Close Dec 20 16:00 ET

3.500
+0.010+0.29%

Post 19:56 ET

520.29MMarket Cap-8.12P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference
BusinesswireNov 26 07:00 ET
When Will Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Become Profitable?
Simply Wall StNov 16 08:47 ET
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $5
Moomoo NewsNov 11 09:31 ET · Ratings
Sapiens International Posts Downbeat Results, Joins Sky Harbour And Other Big Stocks Moving Lower In Monday's Pre-Market Session
BenzingaNov 11 08:16 ET
Xeris Biopharma Price Target Maintained With a $3.00/Share by Piper Sandler
Dow JonesNov 11 06:58 ET · Ratings
Xeris Biopharma Holdings Analyst Ratings
BenzingaNov 11 06:45 ET · Ratings

Comments

earf321

Oct 17 13:21

$Xeris Pharmaceuticals (XERS.US)$ when will we see a new record high?

Trytosaveabit

Jul 8 06:14

Hmm

$Xeris Pharmaceuticals (XERS.US)$ Xeris Biopharma Reports Preliminary Q2 Total Revenue To Exceed $47M, Representing Over 23% Growth Over Last Year; Estimate $44.894M

Trytosaveabit

May 30 13:16

$Xeris Pharmaceuticals (XERS.US)$ And you were doing so lovely! Oh well still a nice PI on fairly benign PR as far as a catalyst for moving up

Trytosaveabit

May 30 06:35

Update

$Xeris Pharmaceuticals (XERS.US)$ Xeris Biopharma Holdings Inc - FDA End-of-Phase 2 Interaction to Facilitate a Phase 3 Pivotal Study Program Is Expected by Year-End

Jaguar8

May 30 06:31

NEWS

$Xeris Pharmaceuticals (XERS.US)$
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
Xeris Biopharma announced positive topline results from its Phase 2 study of XP-8121, a once-weekly subcutaneous levothyroxine (SC) formulation. The study showed that XP-8121 provides predictable bioavailability and sustained levothyroxine levels, achieving normalized TSH/T4 levels with 45% less drug...

Heat List

Overall

No Data